Last updated on January 2020

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy


Brief description of study

The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior VEGFR-Targeted therapy.

Clinical Study Identifier: NCT03690388

Find a site near you

Start Over

Exelixis Clinical Site #95

Strasbourg Cedex, France
6.92miles
  Connect »